A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)

Table 3 Association between AR haplotypes and breast cancer risk in the NCI BPC3

Haplotype	Percentage in cases (n = 5,584)	Percentage in controls (n = 7,459)	OR^a (95% CI)
AGGAAA	0.72	0.71	1.00 (Ref.)
GAAAGG	0.08	0.08	1.01 (0.93 to 1.11)
AAAAAG	0.06	0.07	0.94 (0.85 to 1.03)
AGGGAA	0.05	0.05	0.97 (0.87 to 1.08)
AGGAAG	0.05	0.05	1.02 (0.91 to 1.15)
GAAAAG	0.02	0.02	0.99 (0.83 to 1.18)
AGAAAG	0.02	0.01	0.98 (0.82 to 1.18)
<5%	0.02	0.01	1.18 (0.98 to 1.43)

^aUnadjusted logistic regression, conditional on matching factors and cohort as described in text. AR, androgen receptor; CI, confidence interval; NCI BPC3, National Cancer Institute Breast and Prostate Cancer Cohort Consortium; OR, odds ratio; Ref., Reference category.

ISSN: 1465-542X